NATION IN BRIEF : NEW YORK : FDA OKs Drug for Infant Lung Disease
From Times Staff and Wire Reports
The Food and Drug Administration said it has approved a drug that company studies have shown can cut by 50% the death rate in premature infants suffering from a severe lung disease. The disease, called respiratory distress syndrome, is the most common cause of death in infants younger than 30 days, the American Lung Assn. said in New York. The drug, Exosurf, mimics the action of lung surfactant, a liquid that helps keep lungs inflated.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
